437 Resources in

Medshorts

By month
Derma
2 Min Read
24 Jul

Safety and efficacy of baricitinib in severe alopecia areata patients

A recent study found that in patients with severe alopecia areata (AA), baricitinib demonstrated a high level of efficacy maintenance for a duration of 104 weeks. The effectiveness notably escalated in Week-52 mixed responders, underscoring the significance of long-term treatment needed to observe the maximum benefit in certain patients. This study’s results were published in the Journal of the European Academy of Dermatology and Venereology.

Data from the BRAVE-AA1 and BRAVE-AA2 Phase 3 trials was integrated, involving adults with Severity of Alopecia Tool (SALT) scores of 50 or higher (indicating ≥50% scalp hair loss) who were randomly assigned to receive and consistently take either 2-mg or 4-mg baricitinib up to Week 104. Patients who were eligible to continue receiving treatment were those who had a SALT score of ≤20 at Week 52 [N=65, 2-mg dose; N=129, 4-mg dose; Week-52 responders]. Additionally, patients who received the 4-mg dose and initially had a SALT score >20 at Week 52 but achieved SALT score ≤20 at previous visits and/or had significant improvement in eyebrow or eyelash hair growth compared to their baseline by Week 52 were also considered for continuous treatment [N=110; Week-52 mixed responders]. The Week-104 outcomes were assessed based on the proportion of patients who achieved a SALT score of ≤20 (indicating ≤20% scalp hair loss).

At Week 104, 90.7% of patients treated with 4 mg of baricitinib and 89.2% of those treated with 2 mg of baricitinib who responded positively at Week 52 maintained a SALT score of ≤20. Among the mixed responders at Week 52, 39.1% achieved a SALT score of ≤20 by Week 104. Enhanced eyelash and eyebrow regrowth was consistently noted in every group.

Thus, it can be concluded that over a duration of 104 weeks, baricitinib showcased a remarkable ability to maintain efficacy in patients with severe AA. Notably, Week-52 mixed responders experienced an increase in efficacy, emphasizing the necessity of long-term treatment to observe the maximum benefits in specific individuals.

Safety and efficacy of baricitinib in severe alopecia areata patients

A recent study found that in patients with severe alopecia areata (AA), baricitinib demonstrated a high level of efficacy maintenance for a duration of 104 weeks. The effectiveness notably escalated in Week-52 mixed responders, underscoring the significance of long-term treatment needed to observe the maximum benefit in certain patients. This study’s results were published in the Journal of the European Academy of Dermatology and Venereology.

Data from the BRAVE-AA1 and BRAVE-AA2 Phase 3 trials was integrated, involving adults with Severity of Alopecia Tool (SALT) scores of 50 or higher (indicating ≥50% scalp hair loss) who were randomly assigned to receive and consistently take either 2-mg or 4-mg baricitinib up to Week 104. Patients who were eligible to continue receiving treatment were those who had a SALT score of ≤20 at Week 52 [N=65, 2-mg dose; N=129, 4-mg dose; Week-52 responders]. Additionally, patients who received the 4-mg dose and initially had a SALT score >20 at Week 52 but achieved SALT score ≤20 at previous visits and/or had significant improvement in eyebrow or eyelash hair growth compared to their baseline by Week 52 were also considered for continuous treatment [N=110; Week-52 mixed responders]. The Week-104 outcomes were assessed based on the proportion of patients who achieved a SALT score of ≤20 (indicating ≤20% scalp hair loss).

At Week 104, 90.7% of patients treated with 4 mg of baricitinib and 89.2% of those treated with 2 mg of baricitinib who responded positively at Week 52 maintained a SALT score of ≤20. Among the mixed responders at Week 52, 39.1% achieved a SALT score of ≤20 by Week 104. Enhanced eyelash and eyebrow regrowth was consistently noted in every group.

Thus, it can be concluded that over a duration of 104 weeks, baricitinib showcased a remarkable ability to maintain efficacy in patients with severe AA. Notably, Week-52 mixed responders experienced an increase in efficacy, emphasizing the necessity of long-term treatment to observe the maximum benefits in specific individuals.

Derma
2 Min Read
24 Jul

Safety and efficacy of baricitinib in severe alopecia areata patients

A recent study found that in patients with severe alopecia areata (AA), baricitinib demonstrated a high level of efficacy maintenance for a duration of 104 weeks. The effectiveness notably escalated in Week-52 mixed responders, underscoring the significance of long-term treatment needed to observe the maximum benefit in certain patients. This study’s results were published in the Journal of the European Academy of Dermatology and Venereology.

Data from the BRAVE-AA1 and BRAVE-AA2 Phase 3 trials was integrated, involving adults with Severity of Alopecia Tool (SALT) scores of 50 or higher (indicating ≥50% scalp hair loss) who were randomly assigned to receive and consistently take either 2-mg or 4-mg baricitinib up to Week 104. Patients who were eligible to continue receiving treatment were those who had a SALT score of ≤20 at Week 52 [N=65, 2-mg dose; N=129, 4-mg dose; Week-52 responders]. Additionally, patients who received the 4-mg dose and initially had a SALT score >20 at Week 52 but achieved SALT score ≤20 at previous visits and/or had significant improvement in eyebrow or eyelash hair growth compared to their baseline by Week 52 were also considered for continuous treatment [N=110; Week-52 mixed responders]. The Week-104 outcomes were assessed based on the proportion of patients who achieved a SALT score of ≤20 (indicating ≤20% scalp hair loss).

At Week 104, 90.7% of patients treated with 4 mg of baricitinib and 89.2% of those treated with 2 mg of baricitinib who responded positively at Week 52 maintained a SALT score of ≤20. Among the mixed responders at Week 52, 39.1% achieved a SALT score of ≤20 by Week 104. Enhanced eyelash and eyebrow regrowth was consistently noted in every group.

Thus, it can be concluded that over a duration of 104 weeks, baricitinib showcased a remarkable ability to maintain efficacy in patients with severe AA. Notably, Week-52 mixed responders experienced an increase in efficacy, emphasizing the necessity of long-term treatment to observe the maximum benefits in specific individuals.

button
Cardiac
1 Min Read
23 Jul

Higher Treatment Satisfaction and Convenience scores in patients treated with edoxaban

A recent study suggests that patients with atrial fibrillation after successful transcatheter aortic valve replacement (TAVR) showed significantly more satisfied Treatment Satisfaction and Convenience scores with edoxaban. The results of this study were published in The American Journal of Cardiology.

The ENVISAGE-TAVI AF trial was a prospective, randomized, open-label study that included patients who were randomized to receive either edoxaban (n=585) or VKA-treated (n=522). Pre and post-TAVR Treatment Satisfaction and Convenience were analyzed using the Perception of Anticoagulation Treatment Questionnaire (PACT-Q), that included assessment at baseline (PACT-Q1) and ≥1 post baseline assessment (PACT-Q2). Patients stratified by pre-TAVR anticoagulant (NOAC, VKA, or no NOAC/VKA) were included in subanalyses.

After TAVR (Transcatheter Aortic Valve Replacement), edoxaban-treated patients showed significantly higher Treatment Satisfaction and Convenience scores compared with VKA-treated patients across all time points. Among edoxaban-treated patients, those who received VKAs pre-TAVR were reportedly more satisfied with treatment than those who received non-vitamin K oral anticoagulants (NOACs) or NOACs/VKAs.

Based on the above results, it can be concluded that patients with atrial fibrillation who were administered edoxaban post-TAVR may show significantly higher Treatment Satisfaction and Convenience scores compared with those who received VKAs.

Higher Treatment Satisfaction and Convenience scores in patients treated with edoxaban

A recent study suggests that patients with atrial fibrillation after successful transcatheter aortic valve replacement (TAVR) showed significantly more satisfied Treatment Satisfaction and Convenience scores with edoxaban. The results of this study were published in The American Journal of Cardiology.

The ENVISAGE-TAVI AF trial was a prospective, randomized, open-label study that included patients who were randomized to receive either edoxaban (n=585) or VKA-treated (n=522). Pre and post-TAVR Treatment Satisfaction and Convenience were analyzed using the Perception of Anticoagulation Treatment Questionnaire (PACT-Q), that included assessment at baseline (PACT-Q1) and ≥1 post baseline assessment (PACT-Q2). Patients stratified by pre-TAVR anticoagulant (NOAC, VKA, or no NOAC/VKA) were included in subanalyses.

After TAVR (Transcatheter Aortic Valve Replacement), edoxaban-treated patients showed significantly higher Treatment Satisfaction and Convenience scores compared with VKA-treated patients across all time points. Among edoxaban-treated patients, those who received VKAs pre-TAVR were reportedly more satisfied with treatment than those who received non-vitamin K oral anticoagulants (NOACs) or NOACs/VKAs.

Based on the above results, it can be concluded that patients with atrial fibrillation who were administered edoxaban post-TAVR may show significantly higher Treatment Satisfaction and Convenience scores compared with those who received VKAs.

Cardiac
1 Min Read
23 Jul

Higher Treatment Satisfaction and Convenience scores in patients treated with edoxaban

A recent study suggests that patients with atrial fibrillation after successful transcatheter aortic valve replacement (TAVR) showed significantly more satisfied Treatment Satisfaction and Convenience scores with edoxaban. The results of this study were published in The American Journal of Cardiology.

The ENVISAGE-TAVI AF trial was a prospective, randomized, open-label study that included patients who were randomized to receive either edoxaban (n=585) or VKA-treated (n=522). Pre and post-TAVR Treatment Satisfaction and Convenience were analyzed using the Perception of Anticoagulation Treatment Questionnaire (PACT-Q), that included assessment at baseline (PACT-Q1) and ≥1 post baseline assessment (PACT-Q2). Patients stratified by pre-TAVR anticoagulant (NOAC, VKA, or no NOAC/VKA) were included in subanalyses.

After TAVR (Transcatheter Aortic Valve Replacement), edoxaban-treated patients showed significantly higher Treatment Satisfaction and Convenience scores compared with VKA-treated patients across all time points. Among edoxaban-treated patients, those who received VKAs pre-TAVR were reportedly more satisfied with treatment than those who received non-vitamin K oral anticoagulants (NOACs) or NOACs/VKAs.

Based on the above results, it can be concluded that patients with atrial fibrillation who were administered edoxaban post-TAVR may show significantly higher Treatment Satisfaction and Convenience scores compared with those who received VKAs.

button
Blood Related
2 Min Read
22 Jul

Efficacy of intravenous ferric derisomaltose in pregnant women with persistent iron deficiency

According to a recent study, intravenous (IV) iron (ferric derisomaltose) is more efficacious than oral iron (ferrous fumarate) in women 14-21 weeks pregnant with persistent iron deficiency (ferritin < 30 µg/L). The results of this study were published in the Archives of Gynecology and Obstetrics.

This trial was a single-centre, randomized controlled study that included 201 women with persistent iron deficiency after routine oral iron treatment. They were allocated to receive 1000 mg IV iron (single-dose) or 100 mg elemental oral iron daily. The primary endpoint of the study measured during an 18-week follow-up period was the proportion of non-anaemic (haemoglobin [Hb] ≥ 11 g/dL) women throughout follow-up.

It was observed that 91% of women were non-anaemic in the IV iron group compared with 73% in the oral iron group. The mean Hb increase was significantly greater with IV iron versus oral iron at Weeks 6, 12, and 18. Improvements in fatigue and quality of life (QoL) were greater with IV iron versus oral iron at Weeks 3 and 6. Thus, it can be concluded that IV iron may be superior in preventing anaemia compared with oral iron in pregnant women with persistent iron deficiency.

Efficacy of intravenous ferric derisomaltose in pregnant women with persistent iron deficiency

According to a recent study, intravenous (IV) iron (ferric derisomaltose) is more efficacious than oral iron (ferrous fumarate) in women 14-21 weeks pregnant with persistent iron deficiency (ferritin < 30 µg/L). The results of this study were published in the Archives of Gynecology and Obstetrics.

This trial was a single-centre, randomized controlled study that included 201 women with persistent iron deficiency after routine oral iron treatment. They were allocated to receive 1000 mg IV iron (single-dose) or 100 mg elemental oral iron daily. The primary endpoint of the study measured during an 18-week follow-up period was the proportion of non-anaemic (haemoglobin [Hb] ≥ 11 g/dL) women throughout follow-up.

It was observed that 91% of women were non-anaemic in the IV iron group compared with 73% in the oral iron group. The mean Hb increase was significantly greater with IV iron versus oral iron at Weeks 6, 12, and 18. Improvements in fatigue and quality of life (QoL) were greater with IV iron versus oral iron at Weeks 3 and 6. Thus, it can be concluded that IV iron may be superior in preventing anaemia compared with oral iron in pregnant women with persistent iron deficiency.

Blood Related
2 Min Read
22 Jul

Efficacy of intravenous ferric derisomaltose in pregnant women with persistent iron deficiency

According to a recent study, intravenous (IV) iron (ferric derisomaltose) is more efficacious than oral iron (ferrous fumarate) in women 14-21 weeks pregnant with persistent iron deficiency (ferritin < 30 µg/L). The results of this study were published in the Archives of Gynecology and Obstetrics.

This trial was a single-centre, randomized controlled study that included 201 women with persistent iron deficiency after routine oral iron treatment. They were allocated to receive 1000 mg IV iron (single-dose) or 100 mg elemental oral iron daily. The primary endpoint of the study measured during an 18-week follow-up period was the proportion of non-anaemic (haemoglobin [Hb] ≥ 11 g/dL) women throughout follow-up.

It was observed that 91% of women were non-anaemic in the IV iron group compared with 73% in the oral iron group. The mean Hb increase was significantly greater with IV iron versus oral iron at Weeks 6, 12, and 18. Improvements in fatigue and quality of life (QoL) were greater with IV iron versus oral iron at Weeks 3 and 6. Thus, it can be concluded that IV iron may be superior in preventing anaemia compared with oral iron in pregnant women with persistent iron deficiency.

button
Gastro
2 Min Read
22 Jul

Risankizumab is safe and effective in patients with Crohn's disease

A recent study found that risankizumab, an anti-interleukin-23 antibody is safe and effective in patients with moderate-to-severe Crohn’s disease. This study’s findings were published in the Journal of Gastroenterology and Hepatology.

This was a post hoc sub analysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. ADVANCE and MOTIVATE were double-blind, placebo-controlled, phase 3 induction studies that included a total of 198 patients who had previously experienced intolerance or inadequate response to biologic (MOTIVATE) or a conventional therapy (ADVANCE). The participants were randomized to receive intravenous risankizumab (600 or 1200 mg) or placebo at weeks 0, 4, and 8. The clinical responders to risankizumab entered the placebo-controlled maintenance withdrawal study (FORTIFY). Patients were re-randomized to receive subcutaneous risankizumab (180 or 360 mg) or placebo (withdrawal) every 8 weeks for 52 weeks.

Among 198 patients in the induction studies, the rates of clinical remission and endoscopic response at week 12 were achieved by 61.4% and 40.0% of patients in the risankizumab 600 mg group, 59.5% and 35.8% of patients in the risankizumab 1200 mg group, and 27.3% and 9.1% of patients in the placebo group, respectively. At week 52, among 67 patients who entered the maintenance study, clinical remission and endoscopic response rates were achieved by 57.1% and 52.4% of patients in the risankizumab 180 mg group, 75.0% and 40.0% of patients in the risankizumab 360 mg group, and 53.8% and 34.6% of patients in the placebo (withdrawal) group. Additionally, it was observed that fistula closure was observed in 28.6% (induction) and 57.1% (maintenance) of patients with risankizumab treatment.

Based on the above findings, it may be concluded that risankizumab was effective and well tolerated in patients with Crohn's disease.

Risankizumab is safe and effective in patients with Crohn's disease

A recent study found that risankizumab, an anti-interleukin-23 antibody is safe and effective in patients with moderate-to-severe Crohn’s disease. This study’s findings were published in the Journal of Gastroenterology and Hepatology.

This was a post hoc sub analysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. ADVANCE and MOTIVATE were double-blind, placebo-controlled, phase 3 induction studies that included a total of 198 patients who had previously experienced intolerance or inadequate response to biologic (MOTIVATE) or a conventional therapy (ADVANCE). The participants were randomized to receive intravenous risankizumab (600 or 1200 mg) or placebo at weeks 0, 4, and 8. The clinical responders to risankizumab entered the placebo-controlled maintenance withdrawal study (FORTIFY). Patients were re-randomized to receive subcutaneous risankizumab (180 or 360 mg) or placebo (withdrawal) every 8 weeks for 52 weeks.

Among 198 patients in the induction studies, the rates of clinical remission and endoscopic response at week 12 were achieved by 61.4% and 40.0% of patients in the risankizumab 600 mg group, 59.5% and 35.8% of patients in the risankizumab 1200 mg group, and 27.3% and 9.1% of patients in the placebo group, respectively. At week 52, among 67 patients who entered the maintenance study, clinical remission and endoscopic response rates were achieved by 57.1% and 52.4% of patients in the risankizumab 180 mg group, 75.0% and 40.0% of patients in the risankizumab 360 mg group, and 53.8% and 34.6% of patients in the placebo (withdrawal) group. Additionally, it was observed that fistula closure was observed in 28.6% (induction) and 57.1% (maintenance) of patients with risankizumab treatment.

Based on the above findings, it may be concluded that risankizumab was effective and well tolerated in patients with Crohn's disease.

Gastro
2 Min Read
22 Jul

Risankizumab is safe and effective in patients with Crohn's disease

A recent study found that risankizumab, an anti-interleukin-23 antibody is safe and effective in patients with moderate-to-severe Crohn’s disease. This study’s findings were published in the Journal of Gastroenterology and Hepatology.

This was a post hoc sub analysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. ADVANCE and MOTIVATE were double-blind, placebo-controlled, phase 3 induction studies that included a total of 198 patients who had previously experienced intolerance or inadequate response to biologic (MOTIVATE) or a conventional therapy (ADVANCE). The participants were randomized to receive intravenous risankizumab (600 or 1200 mg) or placebo at weeks 0, 4, and 8. The clinical responders to risankizumab entered the placebo-controlled maintenance withdrawal study (FORTIFY). Patients were re-randomized to receive subcutaneous risankizumab (180 or 360 mg) or placebo (withdrawal) every 8 weeks for 52 weeks.

Among 198 patients in the induction studies, the rates of clinical remission and endoscopic response at week 12 were achieved by 61.4% and 40.0% of patients in the risankizumab 600 mg group, 59.5% and 35.8% of patients in the risankizumab 1200 mg group, and 27.3% and 9.1% of patients in the placebo group, respectively. At week 52, among 67 patients who entered the maintenance study, clinical remission and endoscopic response rates were achieved by 57.1% and 52.4% of patients in the risankizumab 180 mg group, 75.0% and 40.0% of patients in the risankizumab 360 mg group, and 53.8% and 34.6% of patients in the placebo (withdrawal) group. Additionally, it was observed that fistula closure was observed in 28.6% (induction) and 57.1% (maintenance) of patients with risankizumab treatment.

Based on the above findings, it may be concluded that risankizumab was effective and well tolerated in patients with Crohn's disease.

button
Derma
2 Min Read
19 Jul

Bonito elastin peptide improves biophysical properties in aging skin

A recent study found that Bonito elastin peptide (VGPG Elastin®) when taken orally has been shown to diminish fine wrinkles, lower melanin levels, and improve skin hydration. This study’s results were published in the journal, Skin research and technology.

In this double-blinded, randomized, placebo-controlled trial, a total of 100 participants were randomly divided into two groups, with one group receiving a test product that contained 100 mg of Bonito elastin peptide (VGPG Elastin®), while the other group received a placebo. The parameters of hydration, skin wrinkles, and brightening (melanin index) were measured at the start of the study and subsequently at 4, 8, and 12 weeks after the intervention.

After 12 weeks of intervention, the test group demonstrated considerable enhancements in average skin roughness, maximum peak height of the wrinkle, maximum peak-to-valley values,  average maximum height of the wrinkle, maximum valley depth of the wrinkle, and eye wrinkle volume when compared to the placebo group. Additionally, skin hydration levels improved, and the melanin index was significantly lower in the test group than in the placebo group. Notably, no adverse events related to the test product were reported by any participant.

Thus, it can be concluded that oral consumption of Bonito elastin peptide (VGPG Elastin®) effectively reduces the appearance of fine wrinkles, decrease melanin index, and improve skin hydration. These findings suggest that it may be a potential treatment option for combating wrinkles, dryness, and pigmentation issues.

Bonito elastin peptide improves biophysical properties in aging skin

A recent study found that Bonito elastin peptide (VGPG Elastin®) when taken orally has been shown to diminish fine wrinkles, lower melanin levels, and improve skin hydration. This study’s results were published in the journal, Skin research and technology.

In this double-blinded, randomized, placebo-controlled trial, a total of 100 participants were randomly divided into two groups, with one group receiving a test product that contained 100 mg of Bonito elastin peptide (VGPG Elastin®), while the other group received a placebo. The parameters of hydration, skin wrinkles, and brightening (melanin index) were measured at the start of the study and subsequently at 4, 8, and 12 weeks after the intervention.

After 12 weeks of intervention, the test group demonstrated considerable enhancements in average skin roughness, maximum peak height of the wrinkle, maximum peak-to-valley values,  average maximum height of the wrinkle, maximum valley depth of the wrinkle, and eye wrinkle volume when compared to the placebo group. Additionally, skin hydration levels improved, and the melanin index was significantly lower in the test group than in the placebo group. Notably, no adverse events related to the test product were reported by any participant.

Thus, it can be concluded that oral consumption of Bonito elastin peptide (VGPG Elastin®) effectively reduces the appearance of fine wrinkles, decrease melanin index, and improve skin hydration. These findings suggest that it may be a potential treatment option for combating wrinkles, dryness, and pigmentation issues.

Derma
2 Min Read
19 Jul

Bonito elastin peptide improves biophysical properties in aging skin

A recent study found that Bonito elastin peptide (VGPG Elastin®) when taken orally has been shown to diminish fine wrinkles, lower melanin levels, and improve skin hydration. This study’s results were published in the journal, Skin research and technology.

In this double-blinded, randomized, placebo-controlled trial, a total of 100 participants were randomly divided into two groups, with one group receiving a test product that contained 100 mg of Bonito elastin peptide (VGPG Elastin®), while the other group received a placebo. The parameters of hydration, skin wrinkles, and brightening (melanin index) were measured at the start of the study and subsequently at 4, 8, and 12 weeks after the intervention.

After 12 weeks of intervention, the test group demonstrated considerable enhancements in average skin roughness, maximum peak height of the wrinkle, maximum peak-to-valley values,  average maximum height of the wrinkle, maximum valley depth of the wrinkle, and eye wrinkle volume when compared to the placebo group. Additionally, skin hydration levels improved, and the melanin index was significantly lower in the test group than in the placebo group. Notably, no adverse events related to the test product were reported by any participant.

Thus, it can be concluded that oral consumption of Bonito elastin peptide (VGPG Elastin®) effectively reduces the appearance of fine wrinkles, decrease melanin index, and improve skin hydration. These findings suggest that it may be a potential treatment option for combating wrinkles, dryness, and pigmentation issues.

button
Pediatric
3 Min Read
19 Jul

Uncovering the future of pediatric research in India by addressing challenges and revealing opportunities

This study examined the present state of pediatric research in India, highlighting challenges like insufficient funding, lack of research facilities, complex regulatory systems, and the increasing prevalence of childhood obesity. Despite these challenges, there are many opportunities for improving child health outcomes through technological advancements. This study was published in the IP International Journal of Medical Paediatrics and Oncology.

This paper provides several applications for improving pediatric health outcomes. Artificial Intelligence (AI) holds very good scope in pediatric research to analyze data, predict disease conditions, and develop individualized treatment plans. It can be beneficial to analyze larger datasets to find out patterns associated with pediatric diseases for early detection and the development of personalized treatment strategies. Integrating AI into general pediatric research and its application can immensely improve healthcare accessibility in India, irrespective of dynamic social and economic scenarios.

Proteomics research allows us to better understand the structure and function of proteins in various diseases; hence, proteomics research is important for investigating disease mechanisms. Similarly, it can be used for monitoring disease susceptibility and progression, monitoring treatment effectiveness, and assessing the likelihood of exacerbations.

Microbiome research can help us to understand the impact of the microbiome on child health and shed light on the relationship between gut bacteria, the immune system, the central nervous system, and metabolic processes.

Nanotechnology opens new possibilities for targeted drug delivery and precision medicine among children. Engineered nanoparticles with increased efficacy and minimal systemic toxicity can be potentially used in the treatment of pediatric cancer and viral infectious diseases.

The use of advanced fetal imaging technology and early treatment can prevent congenital abnormalities. Adolescent health research can help to deal with mental health problems, nutrition deficiency problems, and lifestyle diseases that Indian teenagers are facing today.

Pediatric interventional radiology includes advanced imaging technologies to diagnose and treat various conditions by utilizing minimally invasive procedures with less recovery time and complications. Improving access to interventional radiology in India has the potential to widen treatment options for pediatric cardiac defects, birth defects, and cancer-related issues.

To conclude, pediatric research in India can be transformed by navigating current challenges and seizing emerging opportunities. The integration of AI, microbiome research, nanotechnology, interventional radiology, and the progress in fetal as well as adolescent health will cater for precise diagnosis and personalized treatment plans, leading to improved health outcomes in children and adolescents.

Uncovering the future of pediatric research in India by addressing challenges and revealing opportunities

This study examined the present state of pediatric research in India, highlighting challenges like insufficient funding, lack of research facilities, complex regulatory systems, and the increasing prevalence of childhood obesity. Despite these challenges, there are many opportunities for improving child health outcomes through technological advancements. This study was published in the IP International Journal of Medical Paediatrics and Oncology.

This paper provides several applications for improving pediatric health outcomes. Artificial Intelligence (AI) holds very good scope in pediatric research to analyze data, predict disease conditions, and develop individualized treatment plans. It can be beneficial to analyze larger datasets to find out patterns associated with pediatric diseases for early detection and the development of personalized treatment strategies. Integrating AI into general pediatric research and its application can immensely improve healthcare accessibility in India, irrespective of dynamic social and economic scenarios.

Proteomics research allows us to better understand the structure and function of proteins in various diseases; hence, proteomics research is important for investigating disease mechanisms. Similarly, it can be used for monitoring disease susceptibility and progression, monitoring treatment effectiveness, and assessing the likelihood of exacerbations.

Microbiome research can help us to understand the impact of the microbiome on child health and shed light on the relationship between gut bacteria, the immune system, the central nervous system, and metabolic processes.

Nanotechnology opens new possibilities for targeted drug delivery and precision medicine among children. Engineered nanoparticles with increased efficacy and minimal systemic toxicity can be potentially used in the treatment of pediatric cancer and viral infectious diseases.

The use of advanced fetal imaging technology and early treatment can prevent congenital abnormalities. Adolescent health research can help to deal with mental health problems, nutrition deficiency problems, and lifestyle diseases that Indian teenagers are facing today.

Pediatric interventional radiology includes advanced imaging technologies to diagnose and treat various conditions by utilizing minimally invasive procedures with less recovery time and complications. Improving access to interventional radiology in India has the potential to widen treatment options for pediatric cardiac defects, birth defects, and cancer-related issues.

To conclude, pediatric research in India can be transformed by navigating current challenges and seizing emerging opportunities. The integration of AI, microbiome research, nanotechnology, interventional radiology, and the progress in fetal as well as adolescent health will cater for precise diagnosis and personalized treatment plans, leading to improved health outcomes in children and adolescents.

Pediatric
3 Min Read
19 Jul

Uncovering the future of pediatric research in India by addressing challenges and revealing opportunities

This study examined the present state of pediatric research in India, highlighting challenges like insufficient funding, lack of research facilities, complex regulatory systems, and the increasing prevalence of childhood obesity. Despite these challenges, there are many opportunities for improving child health outcomes through technological advancements. This study was published in the IP International Journal of Medical Paediatrics and Oncology.

This paper provides several applications for improving pediatric health outcomes. Artificial Intelligence (AI) holds very good scope in pediatric research to analyze data, predict disease conditions, and develop individualized treatment plans. It can be beneficial to analyze larger datasets to find out patterns associated with pediatric diseases for early detection and the development of personalized treatment strategies. Integrating AI into general pediatric research and its application can immensely improve healthcare accessibility in India, irrespective of dynamic social and economic scenarios.

Proteomics research allows us to better understand the structure and function of proteins in various diseases; hence, proteomics research is important for investigating disease mechanisms. Similarly, it can be used for monitoring disease susceptibility and progression, monitoring treatment effectiveness, and assessing the likelihood of exacerbations.

Microbiome research can help us to understand the impact of the microbiome on child health and shed light on the relationship between gut bacteria, the immune system, the central nervous system, and metabolic processes.

Nanotechnology opens new possibilities for targeted drug delivery and precision medicine among children. Engineered nanoparticles with increased efficacy and minimal systemic toxicity can be potentially used in the treatment of pediatric cancer and viral infectious diseases.

The use of advanced fetal imaging technology and early treatment can prevent congenital abnormalities. Adolescent health research can help to deal with mental health problems, nutrition deficiency problems, and lifestyle diseases that Indian teenagers are facing today.

Pediatric interventional radiology includes advanced imaging technologies to diagnose and treat various conditions by utilizing minimally invasive procedures with less recovery time and complications. Improving access to interventional radiology in India has the potential to widen treatment options for pediatric cardiac defects, birth defects, and cancer-related issues.

To conclude, pediatric research in India can be transformed by navigating current challenges and seizing emerging opportunities. The integration of AI, microbiome research, nanotechnology, interventional radiology, and the progress in fetal as well as adolescent health will cater for precise diagnosis and personalized treatment plans, leading to improved health outcomes in children and adolescents.

button
Gastro
2 Min Read
18 Jul

Efficacy of botulinum toxin type A (BoNTA) injections for the treatment of faecal incontinence

A recent study suggests that intrarectal botulinum toxin type A (BoNTA) injections are an efficacious treatment for urge faecal incontinence. This study was published in the journal, The Lancet. Gastroenterology & Hepatology.

This phase 3 study was a double-blind, multicentre, randomized trial that included 200 adult patients who had experienced a failure of conservative or surgical treatment or had at least one urgency or faecal incontinence episode per week for a minimum of 3 months. After withdrawals, the patients were randomly assigned in a 1:1 ratio to receive either 200 units of BoNTA (n=96) or an equivalent volume of saline or placebo (n=95) injections. Three months after treatment, the number of episodes of faecal incontinence and urgency recorded in 21-day patient bowel diaries served as the primary endpoint. For the primary analysis, a modified intention-to-treat (mITT) approach was utilized, with adjustment for baseline faecal incontinence and urgency episodes.

At the end of the study, it was observed that in the BoNTA group, the mean number of faecal incontinence and urgency episodes per day, decreased from 1·9 at baseline to 0.8 at 3 months after the injections were administered while in the placebo group, it decreased from 1.4 to 1.0. The trial did not report any serious treatment-related adverse events. The non-serious adverse event (treatment-related or not) that was frequently seen was constipation, seen in 68 patients in the BoNTA group and 38 patients in the placebo group. From the above results, it can be concluded that BoNTA injections are an efficacious treatment for urge faecal incontinence in adult patients.

Efficacy of botulinum toxin type A (BoNTA) injections for the treatment of faecal incontinence

A recent study suggests that intrarectal botulinum toxin type A (BoNTA) injections are an efficacious treatment for urge faecal incontinence. This study was published in the journal, The Lancet. Gastroenterology & Hepatology.

This phase 3 study was a double-blind, multicentre, randomized trial that included 200 adult patients who had experienced a failure of conservative or surgical treatment or had at least one urgency or faecal incontinence episode per week for a minimum of 3 months. After withdrawals, the patients were randomly assigned in a 1:1 ratio to receive either 200 units of BoNTA (n=96) or an equivalent volume of saline or placebo (n=95) injections. Three months after treatment, the number of episodes of faecal incontinence and urgency recorded in 21-day patient bowel diaries served as the primary endpoint. For the primary analysis, a modified intention-to-treat (mITT) approach was utilized, with adjustment for baseline faecal incontinence and urgency episodes.

At the end of the study, it was observed that in the BoNTA group, the mean number of faecal incontinence and urgency episodes per day, decreased from 1·9 at baseline to 0.8 at 3 months after the injections were administered while in the placebo group, it decreased from 1.4 to 1.0. The trial did not report any serious treatment-related adverse events. The non-serious adverse event (treatment-related or not) that was frequently seen was constipation, seen in 68 patients in the BoNTA group and 38 patients in the placebo group. From the above results, it can be concluded that BoNTA injections are an efficacious treatment for urge faecal incontinence in adult patients.

Gastro
2 Min Read
18 Jul

Efficacy of botulinum toxin type A (BoNTA) injections for the treatment of faecal incontinence

A recent study suggests that intrarectal botulinum toxin type A (BoNTA) injections are an efficacious treatment for urge faecal incontinence. This study was published in the journal, The Lancet. Gastroenterology & Hepatology.

This phase 3 study was a double-blind, multicentre, randomized trial that included 200 adult patients who had experienced a failure of conservative or surgical treatment or had at least one urgency or faecal incontinence episode per week for a minimum of 3 months. After withdrawals, the patients were randomly assigned in a 1:1 ratio to receive either 200 units of BoNTA (n=96) or an equivalent volume of saline or placebo (n=95) injections. Three months after treatment, the number of episodes of faecal incontinence and urgency recorded in 21-day patient bowel diaries served as the primary endpoint. For the primary analysis, a modified intention-to-treat (mITT) approach was utilized, with adjustment for baseline faecal incontinence and urgency episodes.

At the end of the study, it was observed that in the BoNTA group, the mean number of faecal incontinence and urgency episodes per day, decreased from 1·9 at baseline to 0.8 at 3 months after the injections were administered while in the placebo group, it decreased from 1.4 to 1.0. The trial did not report any serious treatment-related adverse events. The non-serious adverse event (treatment-related or not) that was frequently seen was constipation, seen in 68 patients in the BoNTA group and 38 patients in the placebo group. From the above results, it can be concluded that BoNTA injections are an efficacious treatment for urge faecal incontinence in adult patients.

button
Pediatric
2 Min Read
17 Jul

The efficacy of lubiprostone in the treatment of functional constipation in adolescents and children

A recent study has shown that lubiprostone is effective and has good tolerability as a pharmacotherapy for children and adolescents, offering a potential shift in the treatment approach for pediatric functional constipation (FC). This study’s findings were published in the Journal of Pediatric Gastroenterology and Nutrition.

This single-blinded, randomized controlled trial included 280 patients (aged 8-18 years) with FC. These patients were randomly assigned to receive either a weight-based lubiprostone dose (n = 140) or conventional laxatives (n = 140), which included bisacodyl, lactulose, or sodium picosulfate, for a duration of 12 weeks. Subsequently, a 4-week posttreatment follow-up was carried out.

The lubiprostone group demonstrated an improvement in constipation in 91.4% (128 patients) when compared to 34.3% (48 patients) in the conventional therapy group and persisted even after treatment discontinuation. Additionally, within 48 hours of starting the medication, one quarter of the lubiprostone group experienced their first spontaneous bowel movement. Throughout the last 4 weeks of therapy and the subsequent 4 weeks of follow-up, 75.7% of the lubiprostone group maintained a Bristol stool form of 3 or 4 compared to 35.7% (50 patients) in the conventional therapy group. No life-threatening adverse drug reactions were reported, and no patients discontinued treatment due to adverse effects.

Thus, it can be concluded that lubiprostone may be a well-tolerated and effective pharmacotherapy for children and adolescents, presenting a promising alternative in the management of pediatric functional constipation (FC).

The efficacy of lubiprostone in the treatment of functional constipation in adolescents and children

A recent study has shown that lubiprostone is effective and has good tolerability as a pharmacotherapy for children and adolescents, offering a potential shift in the treatment approach for pediatric functional constipation (FC). This study’s findings were published in the Journal of Pediatric Gastroenterology and Nutrition.

This single-blinded, randomized controlled trial included 280 patients (aged 8-18 years) with FC. These patients were randomly assigned to receive either a weight-based lubiprostone dose (n = 140) or conventional laxatives (n = 140), which included bisacodyl, lactulose, or sodium picosulfate, for a duration of 12 weeks. Subsequently, a 4-week posttreatment follow-up was carried out.

The lubiprostone group demonstrated an improvement in constipation in 91.4% (128 patients) when compared to 34.3% (48 patients) in the conventional therapy group and persisted even after treatment discontinuation. Additionally, within 48 hours of starting the medication, one quarter of the lubiprostone group experienced their first spontaneous bowel movement. Throughout the last 4 weeks of therapy and the subsequent 4 weeks of follow-up, 75.7% of the lubiprostone group maintained a Bristol stool form of 3 or 4 compared to 35.7% (50 patients) in the conventional therapy group. No life-threatening adverse drug reactions were reported, and no patients discontinued treatment due to adverse effects.

Thus, it can be concluded that lubiprostone may be a well-tolerated and effective pharmacotherapy for children and adolescents, presenting a promising alternative in the management of pediatric functional constipation (FC).

Pediatric
2 Min Read
17 Jul

The efficacy of lubiprostone in the treatment of functional constipation in adolescents and children

A recent study has shown that lubiprostone is effective and has good tolerability as a pharmacotherapy for children and adolescents, offering a potential shift in the treatment approach for pediatric functional constipation (FC). This study’s findings were published in the Journal of Pediatric Gastroenterology and Nutrition.

This single-blinded, randomized controlled trial included 280 patients (aged 8-18 years) with FC. These patients were randomly assigned to receive either a weight-based lubiprostone dose (n = 140) or conventional laxatives (n = 140), which included bisacodyl, lactulose, or sodium picosulfate, for a duration of 12 weeks. Subsequently, a 4-week posttreatment follow-up was carried out.

The lubiprostone group demonstrated an improvement in constipation in 91.4% (128 patients) when compared to 34.3% (48 patients) in the conventional therapy group and persisted even after treatment discontinuation. Additionally, within 48 hours of starting the medication, one quarter of the lubiprostone group experienced their first spontaneous bowel movement. Throughout the last 4 weeks of therapy and the subsequent 4 weeks of follow-up, 75.7% of the lubiprostone group maintained a Bristol stool form of 3 or 4 compared to 35.7% (50 patients) in the conventional therapy group. No life-threatening adverse drug reactions were reported, and no patients discontinued treatment due to adverse effects.

Thus, it can be concluded that lubiprostone may be a well-tolerated and effective pharmacotherapy for children and adolescents, presenting a promising alternative in the management of pediatric functional constipation (FC).

button
1579 Resources in

Videos

View all
429 Resources in

Webinars

1 Resources in

Courses

View all